Glucose metabolism impairment in major depressive disorder
Major depressive disorder (MDD) is a common mental disorder with chronic tendencies that seriously affect regular work, life, and study. However, its exact pathogenesis remains unclear. Patients with MDD experience systemic and localized impairments in glucose metabolism throughout the disease cours...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-02-01
|
| Series: | Brain Research Bulletin |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S0361923025000036 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1825206992886562816 |
|---|---|
| author | Fanhao Meng Jing Wang Long Wang Wei Zou |
| author_facet | Fanhao Meng Jing Wang Long Wang Wei Zou |
| author_sort | Fanhao Meng |
| collection | DOAJ |
| description | Major depressive disorder (MDD) is a common mental disorder with chronic tendencies that seriously affect regular work, life, and study. However, its exact pathogenesis remains unclear. Patients with MDD experience systemic and localized impairments in glucose metabolism throughout the disease course, disrupting various processes such as glucose uptake, glycoprotein transport, glycolysis, the tricarboxylic acid cycle (TCA), and oxidative phosphorylation (OXPHOS). These impairments may result from mechanisms including insulin resistance, hyperglycemia-induced damage, oxidative stress, astrocyte abnormalities, and mitochondrial dysfunction, leading to insufficient energy supply, altered synaptic plasticity, neuronal cell death, and functional and structural damage to reward networks. These mechanical changes contribute to the pathogenesis of MDD and severely interfere with the prognosis. Herein, we summarized the impairment of glucose metabolism and its pathophysiological mechanisms in patients with MDD. In addition, we briefly discussed potential pharmacological interventions for glucose metabolism to alleviate MDD, including glucagon-like peptide-1 receptor agonists, metformin, topical insulin, liraglutide, and pioglitazone, to encourage the development of new therapeutics. |
| format | Article |
| id | doaj-art-f8bd2571f59643fba82a3adcc4af7c3b |
| institution | Kabale University |
| issn | 1873-2747 |
| language | English |
| publishDate | 2025-02-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Brain Research Bulletin |
| spelling | doaj-art-f8bd2571f59643fba82a3adcc4af7c3b2025-02-07T04:46:40ZengElsevierBrain Research Bulletin1873-27472025-02-01221111191Glucose metabolism impairment in major depressive disorderFanhao Meng0Jing Wang1Long Wang2Wei Zou3The Graduate School, Heilongjiang University of Chinese Medicine, Harbin, Heilongjiang 150040, ChinaThe Graduate School, Heilongjiang University of Chinese Medicine, Harbin, Heilongjiang 150040, ChinaFirst Affiliated Hospital, Heilongjiang University of Chinese Medicine, Harbin, Heilongjiang 150040, China; Corresponding authors.First Affiliated Hospital, Heilongjiang University of Chinese Medicine, Harbin, Heilongjiang 150040, China; Corresponding authors.Major depressive disorder (MDD) is a common mental disorder with chronic tendencies that seriously affect regular work, life, and study. However, its exact pathogenesis remains unclear. Patients with MDD experience systemic and localized impairments in glucose metabolism throughout the disease course, disrupting various processes such as glucose uptake, glycoprotein transport, glycolysis, the tricarboxylic acid cycle (TCA), and oxidative phosphorylation (OXPHOS). These impairments may result from mechanisms including insulin resistance, hyperglycemia-induced damage, oxidative stress, astrocyte abnormalities, and mitochondrial dysfunction, leading to insufficient energy supply, altered synaptic plasticity, neuronal cell death, and functional and structural damage to reward networks. These mechanical changes contribute to the pathogenesis of MDD and severely interfere with the prognosis. Herein, we summarized the impairment of glucose metabolism and its pathophysiological mechanisms in patients with MDD. In addition, we briefly discussed potential pharmacological interventions for glucose metabolism to alleviate MDD, including glucagon-like peptide-1 receptor agonists, metformin, topical insulin, liraglutide, and pioglitazone, to encourage the development of new therapeutics.http://www.sciencedirect.com/science/article/pii/S0361923025000036DepressionBrain glucose metabolismInadequate energy supplyInsulin resistanceOxidative stress |
| spellingShingle | Fanhao Meng Jing Wang Long Wang Wei Zou Glucose metabolism impairment in major depressive disorder Brain Research Bulletin Depression Brain glucose metabolism Inadequate energy supply Insulin resistance Oxidative stress |
| title | Glucose metabolism impairment in major depressive disorder |
| title_full | Glucose metabolism impairment in major depressive disorder |
| title_fullStr | Glucose metabolism impairment in major depressive disorder |
| title_full_unstemmed | Glucose metabolism impairment in major depressive disorder |
| title_short | Glucose metabolism impairment in major depressive disorder |
| title_sort | glucose metabolism impairment in major depressive disorder |
| topic | Depression Brain glucose metabolism Inadequate energy supply Insulin resistance Oxidative stress |
| url | http://www.sciencedirect.com/science/article/pii/S0361923025000036 |
| work_keys_str_mv | AT fanhaomeng glucosemetabolismimpairmentinmajordepressivedisorder AT jingwang glucosemetabolismimpairmentinmajordepressivedisorder AT longwang glucosemetabolismimpairmentinmajordepressivedisorder AT weizou glucosemetabolismimpairmentinmajordepressivedisorder |